FDA Peptide Regulations Explained

FDA in brief

The U.S. Food and Drug Administration regulates drugs (including many peptides) through:

• Drug approval for specific indications
• Compounding oversight under 503A and 503B
• Enforcement against unapproved drug sales and unsafe sources

Drug approval

For a peptide to be marketed as an approved drug, the manufacturer must submit data showing safety and effectiveness for a specific use. Examples include certain GLP-1 receptor agonists used for type 2 diabetes and weight management.

Compounding pathways

Section 503A allows licensed pharmacists to compound drugs for individual patients in response to a valid prescription. Substances used in 503A compounding generally must be on the FDA's bulks list or meet specific criteria.

Section 503B allows registered outsourcing facilities to compound larger volumes under more stringent quality standards, without patient-specific prescriptions.

Why peptides are nuanced

Many peptides discussed in the wellness community are not commercially manufactured as FDA-approved drugs. They have historically reached patients through compounding pharmacies. Whether that pathway remains available depends on the FDA's evolving rules for each specific peptide.

Staying current

MedTideUSA tracks FDA updates on peptide regulation. Join the waitlist to receive notifications when changes occur.